Mylan is a step closer to realizing launch of a generic version of Biogen’s $3.3bn Tecfidera (dimethyl fumarate) multiple-sclerosis brand in the US after the originator was denied an injunction pending its appeal of an unfavorable patent decision at the district court level.

A globally co-ordinated approach to sourcing that rewards non-pricing criteria is imperative to bolster the security of the off-patent industry’s supply chain in the wake of the coronavirus pandemic, James Burt tells Generics Bulletin in the second part of our exclusive interview.

Two weeks remain for companies to submit entries to the Global Generics & Biosimilars Awards 2020, with the entry deadline date of 14 August fast approaching ahead of the digital event on 3 November.

Sandoz is seeking an en banc rehearing of a recent appeals court decision that stands to keep its Erelzi biosimilar etanercept rival to Enbrel off the market until 2029 in the US, claiming that the ruling provides a “playbook” for originators to extend patents beyond their legitimate terms.

The World Health Organization has recently added further biosimilar versions of trastuzumab to its list of prequalified products, along with Roche’s original trastuzumab and rituximab brands, Herceptin and MabThera/Rituxan.

Biocon has received another influx of cash for its Biocon Biologics biosimilars arm, with a $30m investment from private equity group Tata Capital. Ahead of plans to realize $1bn of sales by its financial year ending March 2022, Biocon has been reorganizing and financing Biocon Biologics, with an initial public offering also on the cards by 2023.

Eli Lilly has seen sales of its Basaglar insulin glargine hybrid remain static in the second quarter of 2020. However, the company reported total sales for the first half that were up by a tenth compared to the first half of 2019.

A globally co-ordinated approach to sourcing that rewards non-pricing criteria is imperative to bolster the security of the off-patent industry’s supply chain in the wake of the coronavirus pandemic, James Burt tells Generics Bulletin in the second part of our exclusive interview.

Two weeks remain for companies to submit entries to the Global Generics & Biosimilars Awards 2020, with the entry deadline date of 14 August fast approaching ahead of the digital event on 3 November.